TPN-101 Joins Healey Trial After C9orf72 ALS Success
28 May 2025 //
PR NEWSWIRE
Transposon Acquires Portfolio of Novel Nucleoside Analogs
21 Nov 2024 //
CONTRACTPHARMA
Transposon Expands Pipeline with Acquisition of Nucleoside Analogs
21 Nov 2024 //
PR NEWSWIRE
Transposon to Present TPN-101 Data for C9orf72 ALS/FTD at ALS ONE
06 Nov 2024 //
PR NEWSWIRE
Transposon Gets FDA Fast Track For TPN-101 In PSP
21 May 2024 //
PR NEWSWIRE
Transposon Announces Final Results from a Phase 2 Study of Inhibitor TPN-101
12 Feb 2024 //
PR NEWSWIRE